BIOSYNEX SA: 2024 Half-Year Results and Debt Restructuring

BIOSYNEX announces a 26% increase in its turnover in the first half of 2024, reaching €53.7 million. This increase reflects acquisitions and solid organic growth, despite operating profitability affected by non-recurring restructuring costs. The significant share of sales from US acquisitions, representing 22% of turnover, confirms the strategic potential of this region.

At the same time, BIOSYNEX is pursuing a cost rationalization plan and is entering into discussions with its partners to reorganize its debt. As of June 30, 2024, cash flow reached €10.7 million, a significant decrease compared to December 2023. The debt reorganization aims to ensure business continuity, although uncertainties remain.